Clinical Trials Browser

Phase 1 × Lung Neoplasms × gilteritinib × Clear all

NCT06225427 2025-10-20

Gilteritinib for the Treatment of ALK NSCLC

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms